Objective: To investigate the pharmacokinetic effects of Aurantii Fructus Carbon Quantum Dots (AFIC-CDs) on paeoniflorin (PF), the main active component of Paeonia.Methods: Male Kunming mice were randomly divided into three groups: high - dose AFIC - CDs (120 mg·mL^-1) and PF co - administration group (H), low - dose AFIC - CDs (60 mg·mL^-1) and PF co - administration group (L), and PF alone (2.0 mg·mL^-1) group (S). Mice were orally administered mixed solutions of high or low - dose AFIC - CDs with the same dose of PF, or PF alone. Paeoniflorin levels in the mouse blood were determined by indirect competitive enzyme - linked immunosorbent assay(icELISA) using anti - PF monoclonal antibodies, and pharmacokinetic parameters of PF were compared among the groups.Results: Co - administration of AFIC - CDs with PF significantly increased PF blood concentration and the area under the blood concentration - time curve (AUC - t) (P < 0.05, P < 0.01), with increases observed as the AFIC-CDs concentration increased. Compared to PF administration alone, the Cmax of PF in the high - dose and low - dose AFIC - CDs + PF groups increased from (695.43 ± 229.73) ng·mL^-1 to (1 615.31 ± 245.16) ng·mL^-1 and(973.11 ± 155.90) ng·mL^-1, respectively. The AUC - t increased from (90 181.22 ± 20 926.42) ng·min·mL^-1 to(257 510.74 ± 26 729.64) ng·min·mL^-1 and (116 654.67 ± 11 770.02) ng·min·mL^-1, respectively.Conclusion: AFIC - CDs can enhance the bioavailability of PF, providing scientific evidence for clinical co - medication to improve therapeutic efficacy.

Aurantii fructus carbon quantum dots  /  Paeoniflorin  /  Indirect competitive enzyme - linked immunosorbent assay  /  Pharmacokinetics  /  Bioavailability  /  Drug interaction  /  Nanomedicine